C1orf86 Inhibitors
C1orf86 Inhibitors are chemical compounds that reduce the functional activity of the protein C1orf86. The first six inhibitors – U0126, LY294002, Rapamycin, PD98059, Wortmannin, and SP600125 – inhibit upstream components of the MAPK/ERK and PI3K/AKT/mTOR pathways. The functional activity of C1orf86, if it is an effector in these pathways, is decreased as a result of the inhibited upstream signaling events. For instance, U0126 and PD98059 inhibit MEK, which prevents the activation of ERK, thus suppressing downstream signaling events that may involve C1orf86. Similarly, LY294002 and Wortmannin inhibit PI3K, preventing the downstream activation of AKT and subsequent signaling events that could involve C1orf86.
The remaining six inhibitors – SB203580, Akti-1/2, PF-04691502, AZD8055, FR180204, and GSK690693 – also act on components of these pathways, but their targets are slightly different. SB203580, for example, inhibits p38 MAPK, thereby suppressing downstream signaling events that could involve C1orf86. Akti-1/2 inhibits AKT1 and AKT2, preventing downstream signaling events in the PI3K/AKT/mTOR pathway that could involve C1orf86. PF-04691502 and AZD8055 are potent inhibitors of PI3K and mTOR, respectively, both key proteins in the PI3K/AKT/mTOR pathway. These inhibitors suppress the downstream signaling in this pathway, reducing the functional activity of C1orf86 if it's involved in this pathway.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 inhibits PI3K, an upstream activator in the PI3K/AKT/mTOR pathway. This action prevents the phosphorylation of AKT and downstream signaling events. As a result, the functional activity of C1orf86, if it is a downstream effector of this pathway, can be decreased. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin is a specific inhibitor of mTOR, a key protein in the PI3K/AKT/mTOR pathway. By inhibiting mTOR, Rapamycin hampers the downstream signaling events that could involve C1orf86, thereby reducing its functional activity. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059 inhibits MEK, a key component of the MAPK/ERK pathway. By blocking MEK, PD98059 prevents the activation of ERK and subsequent downstream signaling. If C1orf86 is an effector in this pathway, its functional activity would be diminished as a result. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is an inhibitor of PI3K. By inhibiting PI3K, Wortmannin prevents the downstream activation of AKT and subsequent signaling events. If C1orf86 is involved in this pathway, its functional activity would be reduced. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is a selective JNK inhibitor. By inhibiting JNK, SP600125 prevents downstream signaling events that could involve C1orf86 in the JNK/MAPK pathway, thereby reducing C1orf86’s functional activity. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 is an inhibitor of p38 MAPK. By inhibiting p38, SB203580 suppresses downstream MAPK signaling. As a result, the functional activity of C1orf86 can be reduced if it is involved in the p38 MAPK pathway. | ||||||
Akt Inhibitor VIII, Isozyme-Selective, Akti-1/2 | 612847-09-3 | sc-202048 sc-202048A | 1 mg 5 mg | $208.00 $270.00 | 29 | |
Akti-1/2 is an inhibitor of AKT1 and AKT2. By inhibiting these kinases, Akti-1/2 prevents downstream signaling events in the PI3K/AKT/mTOR pathway. If C1orf86 is involved in this pathway, its functional activity would be decreased. | ||||||
AZD8055 | 1009298-09-2 | sc-364424 sc-364424A | 10 mg 50 mg | $163.00 $352.00 | 12 | |
AZD8055 is an mTOR inhibitor. By suppressing mTOR, AZD8055 prevents downstream signaling events in the PI3K/AKT/mTOR pathway. If C1orf86 is involved in this pathway, its functional activity would be reduced. | ||||||
ERK Inhibitor II, FR180204 | 865362-74-9 | sc-203945 sc-203945A sc-203945B sc-203945C | 1 mg 5 mg 10 mg 50 mg | $110.00 $165.00 $239.00 $942.00 | 45 | |
FR180204 is an inhibitor of ERK, a key protein in the MAPK/ERK pathway. By inhibiting ERK, FR180204 suppresses downstream signaling events that could involve C1orf86, thereby reducing its functional activity. | ||||||
GSK 690693 | 937174-76-0 | sc-363280 sc-363280A | 10 mg 50 mg | $255.00 $1071.00 | 4 | |
GSK690693 is an AKT inhibitor. By inhibiting AKT, GSK690693 stops downstream signaling events in the PI3K/AKT/mTOR pathway. If C1orf86 is involved in this pathway, its functional activity would be decreased. | ||||||